Linked Life Data

11484305

Source:http://linkedlifedata.com/resource/pubmed/id/11484305

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20 Suppl
pubmed:dateCreated
2001-8-3
pubmed:abstractText
Low-molecular weight heparins (LMWHs) have become attractive alternatives to standard unfractionated heparin (UFH) for the treatment and prophylaxis of deep vein thrombosis (DVT), and for the management of acute coronary syndrome (ACS). The economic impact of the use of LMWHs has been studied in randomized controlled studies, in demonstration projects in managed care institutions, and in decision models. These studies provide valuable insight into the ways LMWHs can be economically attractive despite higher per unit costs compared with UFH. For the treatment of DVT, the cost benefit of using LMWHs results primarily from the cost shifting from inpatient to outpatient care, and might be limited by the eligibility of patients for outpatient management. In contrast, the attractiveness of LMWHs for ACS and DVT prophylaxis hinges on the increased effectiveness of LMWHs compared with standard UFH.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
H
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1088-0224
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S1054-65; quiz 1066-7
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Economics of low-molecular weight heparins.
pubmed:affiliation
Duke Center for Clinical Health Policy Research, Duke University Medical Center, Durham, North Carolina, USA.
pubmed:publicationType
Journal Article, Review